PE20152032A1 - Compuestos de 3,4-dihidroisoquinolin-2(1h)-il - Google Patents
Compuestos de 3,4-dihidroisoquinolin-2(1h)-ilInfo
- Publication number
- PE20152032A1 PE20152032A1 PE2015002534A PE2015002534A PE20152032A1 PE 20152032 A1 PE20152032 A1 PE 20152032A1 PE 2015002534 A PE2015002534 A PE 2015002534A PE 2015002534 A PE2015002534 A PE 2015002534A PE 20152032 A1 PE20152032 A1 PE 20152032A1
- Authority
- PE
- Peru
- Prior art keywords
- dihydroisoquinolin
- compounds
- halogen
- formula
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invencion se refiere a ciertos compuestos de 3,4 -dihidroisoquinolin-2(1H)-il, particularmente compuestos de formula I, y composiciones farmaceuticas de los mismos. La invencion ademas proporciona metodos para usar un compuestos de formula I para tratar el deterioro cognitivo asociado con la enfermedad de parkinson o esquizofrenia. Donde n es 0,1 o 2, R1 es halogeno, R2 es halogeno, H, etc. R3 es halogeno, H, etc. El compuestos preferido es: 2-(2,6-diclorofenil)-1-[1S,3R)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3-4-dihidroisoquinolin-2(1H)-il]etanona
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361828740P | 2013-05-30 | 2013-05-30 | |
| US201361905329P | 2013-11-18 | 2013-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20152032A1 true PE20152032A1 (es) | 2016-01-28 |
Family
ID=50983199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015002534A PE20152032A1 (es) | 2013-05-30 | 2014-05-27 | Compuestos de 3,4-dihidroisoquinolin-2(1h)-il |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US8962654B2 (es) |
| EP (1) | EP3004061B8 (es) |
| JP (2) | JP6130590B2 (es) |
| KR (1) | KR101808933B1 (es) |
| CN (1) | CN105228985B (es) |
| AP (1) | AP2015008867A0 (es) |
| AU (2) | AU2014274435B2 (es) |
| BR (1) | BR112015029090B1 (es) |
| CA (1) | CA2912849C (es) |
| CL (1) | CL2015003444A1 (es) |
| CR (1) | CR20150622A (es) |
| CY (1) | CY1119361T1 (es) |
| DK (1) | DK3004061T3 (es) |
| DO (1) | DOP2015000289A (es) |
| EA (1) | EA029220B1 (es) |
| ES (1) | ES2647086T3 (es) |
| GT (1) | GT201500334A (es) |
| HR (1) | HRP20171696T1 (es) |
| HU (1) | HUE034607T2 (es) |
| JO (1) | JO3316B1 (es) |
| LT (1) | LT3004061T (es) |
| ME (1) | ME02838B (es) |
| MX (1) | MX373843B (es) |
| MY (1) | MY180751A (es) |
| NZ (1) | NZ713809A (es) |
| PE (1) | PE20152032A1 (es) |
| PH (1) | PH12015502658B1 (es) |
| PL (1) | PL3004061T3 (es) |
| PT (1) | PT3004061T (es) |
| RS (1) | RS56294B1 (es) |
| SG (1) | SG11201509310QA (es) |
| SI (1) | SI3004061T1 (es) |
| TN (1) | TN2015000514A1 (es) |
| TW (2) | TWI691489B (es) |
| UA (1) | UA118759C2 (es) |
| WO (1) | WO2014193781A1 (es) |
| ZA (1) | ZA201508213B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ625712A (en) | 2009-11-27 | 2016-02-26 | Genzyme Corp | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| JO3316B1 (ar) * | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| AR106332A1 (es) * | 2015-10-23 | 2018-01-03 | Lilly Co Eli | Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona |
| CN108884050B (zh) * | 2016-04-13 | 2022-07-05 | Ucb生物制药私人有限公司 | 四氢异喹啉衍生物 |
| EP3585387A4 (en) | 2017-02-21 | 2020-08-12 | Emory University | CHEMIOKIN CXCR4 RECEIVER MODULATORS AND THEIR USES |
| EP3418270A1 (en) | 2017-06-19 | 2018-12-26 | Universidad Complutense De Madrid | Novel biphenylsulfoximines as allosteric modulators of the dopamine d1 receptor |
| CN111432847A (zh) | 2017-12-01 | 2020-07-17 | Ucb生物制药有限责任公司 | 显像剂 |
| TWI725408B (zh) * | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
| TWI831896B (zh) | 2018-12-18 | 2024-02-11 | 美商美國禮來大藥廠 | 用於治療多巴胺性cns病症之ly3154207劑量療法 |
| TWI843678B (zh) * | 2019-06-18 | 2024-05-21 | 美商美國禮來大藥廠 | 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物 |
| MY210361A (en) | 2019-07-01 | 2025-09-13 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
| PH12021552819A1 (en) | 2019-07-01 | 2022-09-28 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
| MD4200280T2 (ro) | 2020-10-07 | 2024-08-31 | Lilly Co Eli | Derivați de fenil-3,4-dihidroizochinolin-2(1H)-il-etan-1-onă în calitate de modulatori alosterici pozitivi ai receptorului de dopamină D1 |
| CN116507332A (zh) | 2020-12-03 | 2023-07-28 | Ucb生物制药有限责任公司 | 八氢异喹啉基衍生物 |
| JP7777589B2 (ja) * | 2020-12-18 | 2025-11-28 | ユーシービー バイオファルマ エスアールエル | ジヒドロイソキノリニル誘導体 |
| ES3004257T3 (en) * | 2020-12-18 | 2025-03-12 | UCB Biopharma SRL | Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone |
| FI4263517T3 (fi) | 2020-12-18 | 2024-12-09 | UCB Biopharma SRL | Substituoitu tetrahydroisokinoliinijohdannainen d1-positiivisena allosteerisenä modulaattorina |
| KR20230121867A (ko) * | 2020-12-18 | 2023-08-21 | 유씨비 바이오파마 에스알엘 | 무정형 고체 분산체 |
| MX2023010540A (es) | 2021-03-08 | 2023-11-24 | Lilly Co Eli | Uso de mevidaleno y otros moduladores alostéricos positivos d1 en el tratamiento de alucinaciones y psicosis relacionadas con la demencia. |
| AU2022234226B2 (en) * | 2021-03-09 | 2025-08-14 | Eli Lilly And Company | Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68910999T2 (de) | 1988-02-19 | 1994-03-24 | Smithkline Beecham Farma | 1,2,3,4-Tetrahydroisoquinoline, Verfharen zu ihrer Herstellung und ihre Verwendung als Kappa-Rezeptor Agonisten. |
| US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| US5236934A (en) * | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
| US5932590A (en) | 1996-12-05 | 1999-08-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| IL137720A0 (en) | 1998-02-18 | 2001-10-31 | Neurosearch As | Compounds and their use as positive ampa receptor modulators |
| JP2004507456A (ja) | 2000-05-11 | 2004-03-11 | ブリストル−マイヤーズ スクイブ カンパニー | 成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体 |
| US7601739B2 (en) | 2003-08-08 | 2009-10-13 | Virgina Commonwealth University | Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases |
| US7541466B2 (en) | 2003-12-23 | 2009-06-02 | Genzyme Corporation | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases |
| RU2009136330A (ru) * | 2007-03-01 | 2011-04-10 | Янссен Фармацевтика Н.В. (Be) | Тетрагидроизохинолиновые соединения в качестве модуляторов гистаминового н3 рецептора |
| US20120252853A1 (en) * | 2011-04-01 | 2012-10-04 | H. Lundbeck A/S | Positive allosteric modulators of nicotinic acetylcholine receptor |
| US9255090B2 (en) | 2011-12-21 | 2016-02-09 | Actelion Pharmaceuticals Ltd. | Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators |
| JO3316B1 (ar) * | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
-
2014
- 2014-05-15 JO JOP/2014/0163A patent/JO3316B1/ar active
- 2014-05-16 TW TW108104751A patent/TWI691489B/zh active
- 2014-05-16 TW TW103117402A patent/TWI691488B/zh active
- 2014-05-27 EA EA201592082A patent/EA029220B1/ru not_active IP Right Cessation
- 2014-05-27 AP AP2015008867A patent/AP2015008867A0/xx unknown
- 2014-05-27 UA UAA201511029A patent/UA118759C2/uk unknown
- 2014-05-27 ES ES14732756.3T patent/ES2647086T3/es active Active
- 2014-05-27 PL PL14732756T patent/PL3004061T3/pl unknown
- 2014-05-27 NZ NZ71380914A patent/NZ713809A/en unknown
- 2014-05-27 SG SG11201509310QA patent/SG11201509310QA/en unknown
- 2014-05-27 PT PT147327563T patent/PT3004061T/pt unknown
- 2014-05-27 WO PCT/US2014/039494 patent/WO2014193781A1/en not_active Ceased
- 2014-05-27 BR BR112015029090-6A patent/BR112015029090B1/pt active IP Right Grant
- 2014-05-27 HU HUE14732756A patent/HUE034607T2/en unknown
- 2014-05-27 AU AU2014274435A patent/AU2014274435B2/en active Active
- 2014-05-27 HR HRP20171696TT patent/HRP20171696T1/hr unknown
- 2014-05-27 EP EP14732756.3A patent/EP3004061B8/en active Active
- 2014-05-27 CA CA2912849A patent/CA2912849C/en active Active
- 2014-05-27 SI SI201430377T patent/SI3004061T1/sl unknown
- 2014-05-27 MY MYPI2015704341A patent/MY180751A/en unknown
- 2014-05-27 ME MEP-2017-221A patent/ME02838B/me unknown
- 2014-05-27 KR KR1020157033616A patent/KR101808933B1/ko active Active
- 2014-05-27 MX MX2015016495A patent/MX373843B/es active IP Right Grant
- 2014-05-27 TN TN2015000514A patent/TN2015000514A1/en unknown
- 2014-05-27 CN CN201480031030.7A patent/CN105228985B/zh active Active
- 2014-05-27 RS RS20170896A patent/RS56294B1/sr unknown
- 2014-05-27 US US14/287,239 patent/US8962654B2/en active Active
- 2014-05-27 PE PE2015002534A patent/PE20152032A1/es unknown
- 2014-05-27 JP JP2016516713A patent/JP6130590B2/ja active Active
- 2014-05-27 LT LTEP14732756.3T patent/LT3004061T/lt unknown
- 2014-05-27 DK DK14732756.3T patent/DK3004061T3/en active
-
2015
- 2015-11-06 ZA ZA2015/08213A patent/ZA201508213B/en unknown
- 2015-11-23 CR CR20150622A patent/CR20150622A/es unknown
- 2015-11-24 CL CL2015003444A patent/CL2015003444A1/es unknown
- 2015-11-26 GT GT201500334A patent/GT201500334A/es unknown
- 2015-11-27 PH PH12015502658A patent/PH12015502658B1/en unknown
- 2015-11-27 DO DO2015000289A patent/DOP2015000289A/es unknown
-
2016
- 2016-10-07 AU AU2016238934A patent/AU2016238934B2/en active Active
-
2017
- 2017-04-13 JP JP2017079775A patent/JP6387433B2/ja active Active
- 2017-10-05 CY CY20171101039T patent/CY1119361T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20152032A1 (es) | Compuestos de 3,4-dihidroisoquinolin-2(1h)-il | |
| AR132854A2 (es) | Compuestos e intermedios que inhiben mdm2 y procesos para fabricar los mismos | |
| MX382599B (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina. | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| DOP2018000103A (es) | Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para tratar enfermedad de parkinson. | |
| PE20170946A1 (es) | 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| EA201691831A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
| EA201691788A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
| MX2016004841A (es) | Compuestos de pirimidina substituidos y su uso como inhibidores de la tirosina cinasa del bazo (syk). | |
| CL2013003068A1 (es) | Compuestos derivados de 2-(etinil-piridin-2-il)-pirazolidin-3-ona, 2-(etinil-pirimidin-2-il)-pirazolidin-3-ona o 2-(etinil-piridazin-3-il)-pirazolidin-3-ona; moduladores alostericos positivos de mglur5; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar la esquizofrenia o enfermedades cognitivas. | |
| AR096310A1 (es) | Compuestos de 3,4-dihidroisoquinolin-2(1h)-ilo | |
| AR110406A1 (es) | 6-amino-5-fluoro-5-(fluorometil)-2,3,4,5-tetrahidropiridin-2-il-fenil-5-(metoxi-d₃)-pirazina-2-carboxamidas y derivados fluorados de las mismas como inhibidores de bace1 | |
| EA201990188A1 (ru) | Производные 5,7-дигидропирролопиридина |